Chongqing Pharmaceutical Holding released its 2026 interim report. Total operating revenue was 40.132 billion yuan, down 2.57% year-on-year. Net profit attributable to the parent company was 254 million yuan, down 9.85% year-on-year. Net cash flow from operating activities was negative 3.609 billion yuan, a decrease of 1.336 billion yuan year-on-year. The company's asset-liability ratio was 75.45%, gross margin was 6.79%, ROE was 2.17%, and diluted earnings per share was 0.15 yuan. The number of shareholders was 48,300, and the top ten shareholders held 64.01% of the total share capital.
C.Q. Pharmaceutical Holding Co LtdNet profit down 9.85% and operating cash flow negative in interim report.
